![Pharma Ignite | Scrip Citeline Commercial](https://images.info.citeline.com/EloquaImages/clients/Citeline/%7B49b4ef7e-233e-41d8-a9b6-7c214e090b9b%7D__CITELINE_NORSTELLA_EMAIL_LP_FOOTER_LOGO.png)
![ThermoFisher Scientific](https://images.info.citeline.com/EloquaImages/clients/Citeline/{02f5d010-57e8-46bf-b14d-7c9ca40abbdb}_7005_logo.png)
Genetic Conversations:
Inspiring Confidence & Fostering Partnerships For Therapy Development
Wednesday May 8th , 2024
Join us at the Baltimore Aquarium for an evening of meaningful conversation and an engaging evening reception, as experts explore the potential of genetic insights and partnerships that contribute to positive change in therapy development.
- Discover ways to ensure reproducibility, product comparability and assay standardization
- Understand benefits and barriers of analytical test for lot release specifications with different technologies
- Learn about areas of collaboration that can accelerate go-to market timelines
Enjoy the Evening
Wednesday May 8th, 2024
Arrival & Networking
7-7.30pm
Panel Discussion
7.30-8.30pm
Reception & Exhibits
8.30-9.30pm
Join The Experts
ENJOY EXCLUSIVE INSIGHTS FROM OUR EXPERT INDUSTRY SPEAKERS.
![](https://images.info.citeline.com/EloquaImages/clients/Citeline/%7B7ec5d86c-debb-476f-a569-c92275411563%7D_7005_speaker-kinnari.png)
Kinnari Patel, PharmD, MBA
President, Head of R&D and Chief Operating Officer
Rocket Pharma
View BioPanel Discussion
Genetic Conversations: Inspiring Confidence & Fostering Partnerships For Therapy Development
Cell and Gene therapies have had an immense impact in the life sciences industry thus far, with continued innovation promising more real-world success in patients with high unmet needs. Genetic analyses are essential in the development of novel life-changing therapies for patients from the discovery phase to commercialization. As the novel therapeutics grow more complex and regulatory compliance increases it is important to optimize the drug development processes and workflows to help accelerate time to market. Data risks and compliance remain critical pain points for biopharma companies, especially smaller organizations that lack the resources and funding to support lengthy clinical trials. Therefore, it is imperative that decision-makers are aware of solutions that streamline and expedite cell and gene therapy development.
Discussion points will include:
- The current gene therapy landscape and associated compliance challenges
- How to streamline genetic analysis workflows to bring therapies to market efficiently
- Key regulatory considerations for advanced therapies, including specifics on mRNA and cell and gene therapies (CGTs)
- Best practices for incorporating compliant technology into genetic analysis workflows
- How to build trust and confidence in data through strategic partnerships
Getting There
National Aquarium
501 E Pratt St,
Baltimore, MD 21202